Intra-Cellular Therapies ... (ITCI)
131.87
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM
0.00% (1D)
| Bid | 131.83 |
| Market Cap | 14.05B |
| Revenue (ttm) | 680.64M |
| Net Income (ttm) | -74.68M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -180.64 |
| Forward PE | 686.6 |
| Analyst | Hold |
| Ask | 131.92 |
| Volume | 16,042,154 |
| Avg. Volume (20D) | 3,575,308 |
| Open | 131.92 |
| Previous Close | 131.87 |
| Day's Range | 131.87 - 131.87 |
| 52-Week Range | 64.09 - 131.98 |
| Beta | 0.46 |
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as ...
Full Company ProfileAnalyst Forecast
According to 13 analyst ratings, the average rating for ITCI stock is "Hold." The 12-month stock price forecast is $99, which is a decrease of -24.93% from the latest price.
Stock ForecastsNext Earnings Release
Intra-Cellular Therapies Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+34.07%
Intra-Cellular Therapies shares are trading higher...
Unlock content with
Pro Subscription
5 months ago
+11.36%
Intra-Cellular Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 net product sales guidance. Also, Needham reiterated a Buy rating on the stock.
3 months ago · https://thefly.com
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson dealIntra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%)
